Results 41 to 50 of about 231,458 (256)
Canonical Antibodies Adopt Distinct Binding Modes to Recognize Viral Glycan Shields
Canonical Y‐shaped antibodies recognize viral glycan shields through adaptive Fab assembly states shaped by glycan organization and somatic hypermutation. Structural analyses ofbroadly neutralizing antibodies VRC35 and VRC36 across glycoproteins of HIV‐1, influenza, SARS‐CoV‐2, and Lassa viruses reveal distinct Fab assembly states, spanning monovalent,
Jiaxuan Cheng +71 more
wiley +1 more source
A mechanically activated SynNotch reporter platform enables detection of force transmission through receptors as they mediate immune cell interactions. Targeting CD40 on B cells and TCR on T cells records force‐induced reporter activation across 2D coculture, 3D organoid, and implanted in mice, which also reveal force‐amplification of immune receptor ...
Menglan Li +9 more
wiley +1 more source
CAQ Corner: Immune‐mediated complications
Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley +1 more source
Background Chimeric antigen receptor natural killer (CAR-NK) cells represent a promising advancement in CAR cell therapy, addressing limitations observed in CAR-T cell therapy.
Na Yang +11 more
doaj +1 more source
Antibody against CD20 in patients with B cell malignancy
Cancer patients may make antibodies against antigens on the surface of their malignant cells due either to the expression of unique antigens or to dysregulated responses to self antigens.
Zola, H. +9 more
core +1 more source
Cryo‐electron microscopy structures reveal two distinct neutralization mechanisms of fully human monoclonal antibodies targeting the Shiga toxin 1a B subunit. RDS059 occludes the Gb3 receptor‐binding site, whereas RDS045 engages a lateral quaternary epitope to disrupt holotoxin assembly.
Jianting Ke +10 more
wiley +1 more source
CD20 role in pathophysiology of Hodgkin’s disease
Summary Hodgkin’s lymphoma (HL) is a tumor comprising non-malignant and malignant B-cells. Classical HL expresses CD15+ and CD30+ antigens, and 20 to 40% of patients are CD20+.
Marcelo Antônio Oliveira Santos +1 more
core +1 more source
A novel hetero‐bivalent agent, 68Ga/177Lu‐FZ‐NF‐1, concurrently targets Nectin‐4 and FAP in triple‐negative breast cancer. It yields significant preclinical tumor regression and clinically identifies additional metastatic lesions missed by 18F‐FDG PET, demonstrating promising theranostic potential for personalized management.
Ye Li +13 more
wiley +1 more source
Lineage Determination of CD20– B-Cell Neoplasms
We studied 61 CD20- B-cell lymphomas, including 29 cases of precursor B-cell lymphoblastic leukemia/lymphoblastic lymphoma (B-ALL/B-LBL), 25 cases of CD20- recurrent mature B-cell lymphoma after rituximab therapy, and 7 cases of CD20- diffuse large B ...
Lawrence M. Weiss +7 more
core +1 more source
Single‐Cell Profiling Reveals Clonally Expanded CX3CR1+ T Cells in Anti‐NMDA Receptor Encephalitis
CX3CR1+ T cells are associated with peripheral and central immune alterations in anti‐NMDA receptor encephalitis (NMDAR‐E). They show potential responsiveness to GluN1 (NR1) peptides, potential interactions with peripheral B cells, clonal expansion, increased CD137/CD154 expression, and inflammatory cytokine production. Their preferential cerebrospinal
Lin Yan +13 more
wiley +1 more source

